Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non‐small cell lung cancer based on bintrafusp alfa trials
Abstract This analysis aimed to quantify tumor dynamics in patients receiving either bintrafusp alfa (BA) or pembrolizumab, by population pharmacokinetic (PK)‐pharmacodynamic modeling, and investigate clinical and molecular covariates describing the variability in tumor dynamics by pharmacometric an...
Saved in:
Main Authors: | Ana‐Marija Milenković‐Grišić (Author), Nadia Terranova (Author), Diane R. Mould (Author), Yulia Vugmeyster (Author), Thomas Mrowiec (Author), Andreas Machl (Author), Pascal Girard (Author), Karthik Venkatakrishnan (Author), Akash Khandelwal (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer
by: Han Liu, et al.
Published: (2023) -
Risk assessment of drug-drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach
by: Yulia Vugmeyster, et al.
Published: (2022) -
Variable or variate? A conundrum in pharmacometrics exposure-response models
by: Ana‐Marija Grisic, et al.
Published: (2023) -
Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trialResearch in context
by: Chi Leung Chiang, et al.
Published: (2023) -
Bullous pemphigoid secondary to bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1
by: Claire J. Wiggins, BS, et al.
Published: (2021)